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WHAT THIS PAPER ADDS
 This study provides histological evidence in an in vivo model to support the clinical impression that sodium tetradecyl sulphate is
more effective than polidocanol for the sclerotherapy of varicose veins. Further it shows that these sclerosants, particularly poli-
docanol cause incomplete endothelial cell loss and minimal injury to the media thus providing a rational explanation for venous
recannalisation and treatment failure.a r t i c l e i n f o
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Objectives: To compare the half-life of STD and Polidocanol air-based foams and the damage they inﬂict
upon human great saphenous vein in an in-vitro model.
Methods: The time for the volume of 3% STD and polidocanol foams to reduce by 10% (T90) and 50% (T50)
was recorded in an incubator at 37 C.
Segments of proximal GSV harvested during varicose vein surgery were ﬁlled with foam for 5 or 15 min.
Histological analysis determined percentage endothelial cell loss and depth of media injury.
Results: Median (IQR) T90 and T50 for polidocanol were 123.3 s (111.7e165.6) and 266.3 s (245.6e383.1)
versus 102.03 s (91.1e112) and 213.13 s (201e231.6) for STD (T90 p ¼ 0.008, T50 p ¼ 0.004).
Median endothelial loss with polidocanol was; 63.5% (62.2e82.8) and 85.9% (83.8e92.5) versus 86.3%
(84.8e93.7) and 97.64% (97.3e97.8) for STD after 5 and 15 min (p ¼ 0.076 and p ¼ 0.009).
The median depth and % media thickness injured were 0 mm (0e0 mm) and 0% for both assessments with
polidocanol versus 37.4 mm (35.3e45.8 and 43.4 mm (42.1e46.7) and 3.5% (3.1e3.6) and 5.3% (3.7e6.0)
after 5 and 15 min for STD (p < 0.01 for all comparisons).
Conclusion: Although polidocanol foam shows greater stability than STD foam perhaps remaining in the
vein for longer, endothelial cell loss and damage to the media were signiﬁcantly greater with STD.
 2012 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Introduction
Although sodium tetradecyl sulphate (STD) and polidocanol are
the two most widely used sclerosant foams for treating varicose
veins1,2 minimal data is available regarding their half-life and the
damage that they inﬂict upon the vein wall.
In the treatment of varicose veins and telangectasia with scle-
rotherapy there is someevidence that STDmaybemoreeffective than: þ44 1133928363.
nhs.uk (M.J. Gough).
Elsevier Ltd on behalf of Europeapolidocanol.3e5 This study focuses on the use of STD and polidocanol
foams for treating truncal veins (GSV). Despite a possibledifference in
efﬁcacy, most literature (including product information) recom-
mends a concentration of 3% for both sclerosants in the treatment of
large superﬁcial varicose or incompetent truncal veins.6e8 A surveyof
members of the Vascular Society of Great Britain and Ireland in 2007
conﬁrmed that this reﬂects current practice.9
Although liquid sclerotherapy has been used for treating retic-
ular veins or telangectasia (3 mm diameter) for almost a century,
foam (1939) and mixing the sclerosant with air (1944) are more
recent inovations.10,11 Interest in foam sclerotherapy for treating
truncal veins increased following Cabrera’s work and ultrasoundn Society for Vascular Surgery.
Table 1
Median T90 and T50 values for STD and polidocanol 3% foams (10 measurements).
STD Polidocanol
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the management of varicose veins.12
Foam prepared using the Tessari technique displaces blood from
the vein and increases both the duration and surface area of contact
between the sclerosant and the vein wall.6,13
Effective sclerosis (ﬁbrosis) of a vein requires endothelial
destruction and exposure of sub-endothelial collagen ﬁbres to the
sclerosant. This initiates the intrinsic pathway of blood coagulation
by activating factor XII. Nevertheless the aim of sclerotherapy is not
to merely achieve vein thrombosis, which may be amenable to
recanalisation, but to achieve transformation into a ﬁbrous cord.14
The latter is more likely to occur where the damage inﬂicted
upon the vein wall involves both the endothelium and the sub-
endothelial medial layer. Whilst this has been demonstrated with
other minimally invasive treatments (endovenous laser ablation
[EVLA] and radiofrequency ablation [RFA]) that are associated with
high ablation rates, little is known about the ability of either STD or
polidocanol to achieve this.15,16 Further, foam sclerotherapy has
early recanalisation rates of up to 32% as well as poor medium to
long-term occlusion rates compared to these other minimally
invasive treatments.17,18 This suggests that the principle mode of
action of these agents is to promote thrombotic occlusion rather
than permanent vein wall injury. Although there is much work
describing the in-vitro effects of sclerosants on coagulation and
cultured cell lines using normal arterial or superﬁcial venous tissue
there is minimal data on their effect on the superﬁcial veins of
patients with varicose veins.19e22 Further there is no literature
comparing the effects of STD and polidocanol on human veins.
The aim of this study was to compare both the stability and
degree of injury inﬂicted by STD and polidocanol in an in-vitro
model using incompetent GSV.
Materials/Methods
In-vitro half-life of 3% STD and 3% polidocanol foams
Foam was prepared using Tessari’s technique (1:3 ratio of scle-
rosant: air) with 20 passes through a double syringe system and
immediately transferred to a preheated (37 C) 15 ml graduated
polyester tube. The initial foam volume was recorded and subse-
quent readings were taken every 30 s until the volume of the foam
fell below 2 mls. Experiments were conducted at 37 C (Stuart
Incubator S16D, Bibby Scientiﬁc Ltd, Staffordshire, UK). 10 runs
were performed for both 3% STD and 3% polidocanol.
Previous research has shown that the rate of destabilisation of
foam is non-linear with periods of apparent stability before sudden
decreases in the volume of foam.23 Further, the initial volume of the
foam varied slightly between experiments. Thus, rate of change in
foam volume cannot be used as a measure of foam stability. Instead
the experimental data was converted to percentage of foam
remaining against time with the time taken for a 10% (T90) and 50%
(T50) decrease in volume used as a measure of foam stability.
In-vitro human great saphenous vein wall treated with STD and
polidocanol
3e5 cm segments of proximal GSV were harvested prior to
stripping from patients undergoing surgery for primary varicose
veins with documented evidence of sapheno-femoral junction (SFJ)
incompetence and GSV reﬂux on ultrasound. A clip was placed on
one end of the test vein that was then ﬁlled with either 3% STD or
polidocanol foam. Each sclerosant was tested blindly (coded A or B).
A second clip was then used to occlude the other end of the
segment. Control samples of the same vein were ﬁlled with the
patient’s blood (heparinised) to account for potential mechanical orpressure effects of ﬂuid in the lumen of the vein. Test and control
sections were simultaneously placed in 2 mLs of patient’s hepari-
nised blood and left in-situ for either 5 or 15 min. Five veins were
tested with each sclerosant for both durations. After the prescribed
time the veins were ﬂushed with heparinised blood and the mid-
portion of each vein (avoiding the clipped ends) was immediately
ﬁxed in 10% buffered formal saline and subsequently sectioned and
stained with haemotoxylin and eosin. Each sample was allocated
a random number (random number generator) to ensure blinding
during histological analysis.
Histological analysis was performed by a consultant cardiovas-
cular pathologist who was blinded in respect of whether samples
were controls or experimental, the duration of the experiment and
the type of sclerosant. 20  magniﬁcation sections were analysed
using an Aperio ImageScope v.10.2.2.2319 (AperioTechnologies, Inc.
Vista, CA, USA) to determine the percentage luminal endothelial
loss and the depth of injury to the media.
To determine the extent of endothelial cell loss the luminal
circumference and the length of endothelial cells remaining were
measured using the Aperio “Pen Tool.” Endothelial cell loss was
calculated as a percentage of the luminal circumference without an
endothelial layer.
The depth of medial injury (mm) and the total depth of themedia
were assessed at the “12 points” of a clock-face in each section and
both the absolute depth of injury (the depth over which sub-
endothelial vacuolation extended from the intima) and the %
depth of injury were determined. Sub-endothelial vacuolation was
characterised by swollen, pale smooth muscle cells, with unravel-
ling of the nucleolus. Two sections from each vein (providing 24
measurements for each parameter) were examined and themedian
(IQR) depth and % depth of injury determined.
Statistical Analysis
Analysis was performed using PASW (SPSS, Statistical Package
for Social Sciences Inc, Chicago, Illinois, USA) version 18.0. The
ManneWhitney U Test was used to compare data. A p value of
<0.05 was considered signiﬁcant.
Results
In-vitro half-life of STD and polidocanol foams
T90 and T50 values are shown in the Table 1 and Fig. 1. The
median T90 and T50 for polidocanol were signiﬁcantly longer than
those for STD (p ¼ 0.008 and p ¼ 0.004 respectively). Thus 3%
polidocanol shows greater stability than 3% STD foam.
In-vitro GSV injury following exposure to STD and polidocanol
Tables 2 and 3 summarise the results for STD and polidocanol at
5 and 15 min.
Mean endothelial loss (Fig. 2) after exposure to polidocanol was
less than that for STD (p ¼ 0.076 and p ¼ 0.009 respectively). By
comparison median endothelial cell loss in controls was negligible
(5.7% and 7.26%).
Figure 1. T90 and T50 (sec) for 3% STD and 3% polidocanol foams.
Table 3
Vein wall injury data for STD and polidocanol at 15 min.
STD 15 min Polidocanol 15 min p
Median endothelial cell
loss (%)
97.6 (97.3e97.9) 85.9 (83.8e92.5) p ¼ 0.009
Median depth of injury (mm) 43.4 (42.1e46.7) 0 (0e0) p ¼ 0.005
Median depth of injury as % of
media thickness (%)
5.3 (3.7e6.0) 0 (0e0) p ¼ 0.007
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thickness injured) was greater with STD compared to polidocanol
(median depth of injury at 5 and 15 min: p < 0.01 for both; %
median thickness injury at 5 and 15 min; p < 0.01 for both). No
medial injury occurred in controls. These data are shown in
Figs. 3 and 4.
Fig. 5 shows a histology slide of GSV treated for 15 min with 3%
STD foam conﬁrming injury to the superﬁcial part of the media
whilst Fig. 6 (3% polidocanol for 15 min) shows intact endothelium
with no discernible media injury. This slide is typical of those for
polidocanol.
Discussion
Despite 150 years of unregulated human experimentation
encompassing a range of more or less toxic agents, the “perfect
sclerosant,” free from complications and causing permanent vein
occlusion has not been found. Thus, currently available sclerosants
represent a compromise between efﬁcacy and toxicity.1
The desired functions of sclerosing agents are the destruction of
venous endothelial cells and exposure of sub-endothelial collagen
ﬁbres, and ultimately ﬁbrotic occlusion of the treated vein.13 Poli-
docanol and STD are detergent agents containing a hydrophilic and
a hydrophobic pole. They act by altering the surface tension around
endothelial cells. The hydrophobic pole binds to the cell surface,
whereas the hydrophilic portion attracts water into the cell,
resulting in a rapid and intense cell hydration.24 Endothelial
damage is enhanced by greater concentrations of sclerosant in
smaller veins and delivery as foam prolongs the time of contact and
ampliﬁes the effect of the agent.13
The current study shows that whilst both sclerosants destroy
the endothelium (to a greater or lesser extent) polidocanol does not
inﬂict a signiﬁcant injury to the media. Whilst STD achieves this
aim the effect is much less than the tissue injury inﬂicted by RFATable 2
Vein wall injury data for STD and polidocanol at 5 min.
STD 5 min Polidocanol 5 min p
Median endothelial cell
loss (%)
86.3 (84.8e93.7) 63.48 (62.2e82.9) p ¼ 0.076
Median depth of injury (mm) 37.4 (35.3e45.8) 0 (0e0) p ¼ 0.007
Median depth of injury as % of
media thickness (%)
3.5 (3.1e3.6) 0 (0e0) p ¼ 0.007and EVLA. These induce heat-dependant changes in collagen in the
vein wall with loss of periodicity, dissolution and fusion of ﬁbres,
coagulation of collagen bundles and shrinking of smooth muscle,
resulting in vessel contraction.25e27
Duplex ultrasound follow-up after truncal vein foam scle-
rotherapy demonstrates recanalisation and recurrent reﬂux in
20e32% of limbs at 1e3 years, compared to a rate of 1e16%
following RFA and EVLA.28e30 It is likely that the more favourable
early and mid-term occlusion rates offered by these techniques are
the result of a greater damage inﬂicted upon the vessel wall. It
therefore appears that denaturing collagen is necessary for
sustainable vessel closure.31
Early treatment failure following sclerotherapy is associated with
recanalisation of the treated vein. On the basis of this work it seems
likely that the initial success of sclerotherapy is associated with
simple thrombotic occlusion and that recanalisation is promoted by
persisting islands of endothelial cells and the absence of signiﬁcant
ﬁbrosis due to the failure to inﬂict a signiﬁcant injury to the media.
Although this hypothesis seems logical this study only assesses
the immediate impact of sclerotherapy in an in vitro model. It is
possible that sclerotherapymay cause greater tissue damage in vivo
and this would be consistent with a similar clinical efﬁcacy for both
sclerosants despite the greater vein wall injury inﬂicted by STD in
this model. One potential mechanism for enhanced in vivo injury
might be vein wall hypoxia following thrombosis.
There are few studies detailing the pathological changes
induced by sclerotherapy on varicose veins. Orsini et al.32 described
changes in the GSV vein wall treated with 3% STD (in-vivo),
reporting complete loss of endothelium after 2 min with sub-
endothelial oedema developing after 15 min exposure to STD.
Ikponmwosa et al.22 found almost complete endothelial cell loss
after exposure to 1% and 3% STD after 2 min but with minimal sub-
endothelial damage and no collagen disruption. These ﬁndings for
STD would seem consistent with those of this study and at the very
least a sclerosant which causes maximal endothelial destruction is
likely to have a longer lasting therapeutic effect. Nevertheless evenFigure 2. Percentage endothelial loss with 3% STD, 3% polidocanol and controls ﬁlled
with heparinised blood at 5 and 15 min.
Figure 3. Depth of injury (mm) by 3% STD, 3% polidocanol and controls ﬁlled with
heparinised blood at 5 and 15 min.
Figure 5. Example of 20  magniﬁcation of in-vitro GSV treated for 15 min with 3%
STD foam. The arrow points to residual foam and two measurements of depth of injury
are marked reﬂecting the depth of the most superﬁcial viable nuclei.
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may still occur via circulating endothelial progenitor cells.33,34
Our results also show that 3% polidocanol foam lasts longer than
3% STD foam with a median difference of 21.3 s and 53.2 s for T90
and T50 respectively. Similar differences between the longevity of
the respective foams have been found by others using different
strengths of these sclerosants.35 This may be related to the larger
molecular size of polidocanol thus enhancing its surfactant and
foaming properties. This ought to be beneﬁcial given that foam
sclerotherapy is considered more efﬁcacious than liquid scle-
rotherapy because of a longer contact time between the sclerosant
and the endothelial cells.13 However, Parsi et al. found that the
therapeutic effect of a sclerosant appears to occur in the ﬁrst few
seconds after injection.19 Thus it is possible that as long as the
active drug is distributed to the target area, longer exposure may
not signiﬁcantly increase its efﬁcacy. Certainly our results suggest
that the longevity of the foam matters less than the active ingre-
dient as evidenced by the difference in sub-endothelial damage
between the two agents.Figure 4. % of media injured by 3% STD, 3% polidocanol and controls ﬁlled with
heparinised blood at 5 and 15 min.The mean depth of injury and the percentage of media injured
were signiﬁcantly higher for STD compared to polidocanol.
Although there are no other histological studies with which to
compare these ﬁndings they would support the clinical view that
STD is a more potent sclerosant than polidocanol with higher
concentrations of the latter necessary to produce the same
effect.3e5,35,36 Nevertheless the EASI study showed that polidocanol
0.5% and 1% were as effective as STD in the treatment of patients
with reticular and spider veins, and that more patients were
satisﬁed with the effect polidocanol because of more adverse
events with STD.14 Similarly, Goldman treated patients with vari-
cose and telangiectatic veins (none with truncal vein incompe-
tence) with either polidocanol (0.5%, 1%) or STD (0.25%, 0.5%) and
observed that polidocanol and STD were equally effective although
tissue necrosis and swelling was less common in the polidocanol
group.4 Rao et al., in the only study using foam also found that the
two sclerosants had similar efﬁcacy, tolerability and patient
satisfaction.5
Although the ﬁndings of this study seem robust it has a number
of shortcomings. These include the relatively small number of veins
tested and its in-vitro design. Ethical considerations make in-vivo
humans studies impossible. Whilst animal models could be used
for in-vivo research expense would preclude large experimental
numbers. In addition there is no established animal model with SFJ
and GSV incompetence.
One advantage of the model used in this study is that it can
easily be used in the initial assessment of longer lasting or novel
sclerosants.Figure 6. Example of 20  magniﬁcation of in-vitro GSV treated for 15 min with 3%
polidocanol foam demonstrating intact endothelium (solid arrow) with no discernible
injury to the media (broken arrow).
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Although polidocanol foam shows greater stability than STD
foam andmay thus remain in the treated segment of vein for longer
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